Prophylactic Therapy of Spontaneous Leukemia in AKR Mice by Polyadenylic-Polyuridylic Acid

Beginning at 7 weeks of age, AKR mice were treated with the synthetic double-stranded polynucleotide, polyadenylic-polyuridylic acid (poly A: U). Of the various doses evaluated, 1500 μg poly A: U administered subcutaneously weekly prolonged dramatically the long-term survival of these mice, which ha...

Full description

Saved in:
Bibliographic Details
Published in:JNCI : Journal of the National Cancer Institute 1974-03, Vol.52 (3), p.941-944
Main Authors: Drake, Walter P., Cimino, Eugene F., Mardiney, Michael R., Sutherland, John C.
Format: Article
Language:English
Subjects:
Animals
BCG Vaccine - therapeutic use
Dose-Response Relationship, Drug
Female
Leukemia, Experimental - drug therapy
Leukemia, Experimental - mortality
Leukemia, Experimental - therapy
Mice
Mice, Inbred AKR
Mycobacterium bovis - immunology
Poly A-U - therapeutic use
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Beginning at 7 weeks of age, AKR mice were treated with the synthetic double-stranded polynucleotide, polyadenylic-polyuridylic acid (poly A: U). Of the various doses evaluated, 1500 μg poly A: U administered subcutaneously weekly prolonged dramatically the long-term survival of these mice, which have a genetic propensity to develop leukemia. The extraordinary lack of toxicity of this agent and its therapeutic effectiveness on a spontaneous animal tumor indicate that poly A: U may eventually be used as a successful anticancer drug in man.
ISSN:0027-8874
1460-2105
DOI:10.1093/jnci/52.3.941